IRCT138812153492N1已完成未知
The effects of nicotinic acid on hyperphosphatemia in dialysis patients of valiasr-Arak center
Depuity of education & research of Arak university of Medical science0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 90 years（—）
- 性别
- All
入选标准
- •Inclusion criteria : Age > 18&<90 years, sign satisfaction, serum phosphorous: 5-7 mg/day , unchanged treatment protocol , (calcium components and Vit D) during last two weeks , unchanged dialysis protocol. Exclusion criteria: pregnancy, known liver disease, active peptic ulcer, carbamazepine use, drug intolerance.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
The effects of Nicotinic acid on serum phosphorus, PTH and lipid profile in dialysis patients .Condition 1: Hyperphosphatemi. Condition 2: Hyperlipidaemia. Condition 3: Hyperparathyroidism.Disorder of phosphorus metabolismMixed hyperlipidaemiaHyperparathyroidism and other disorders of parathyroid glandIRCT201402212954N4Vice chancellor for research, Shahroud University medical and Sciences120
招募中
2 期
PUBLIC TITLE ; Effect of niacin on hyperphosphatemia in chronic kidney disease (stages 3-5) patientsKidney DiseasePACTR201905507865682Edema Oritseweyinmi Great120
进行中（未招募）
不适用
Efficacy of niacin on phosphatic metabolism in patients with renal insufficiencyEUCTR2005-002221-31-DEClinic for Nephrology30
已完成
2 期
Treatment hyperphosphatemia in hemodialysis patienthyperphosphatemia in hemodialysis.Extracorporeal dialysisIRCT201011295275N1Vice chancellor for research, Tabriz University of Medical Sciences and Health Services70
进行中（未招募）
1 期
Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) - NICOLaipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated Lp(a) levels include nicotinic acid (niacin), but there is a lack of randomised controlled studies assessing the effectiveness of these therapies in lowering Lp(a) as a primary endpoint and in reducing cardiovascular events in the long term.EUCTR2006-005710-12-DECharité Universitätsmedizin Berlin150